T0	Interventions 25 35	evolocumab
T1	Interventions 125 143	placebo-controlled
T2	Interventions 443 453	Evolocumab
T3	Interventions 457 476	monoclonal antibody
T4	Interventions 480 525	proprotein convertase subtilisin/kexin type 9
T5	Interventions 611 621	evolocumab
T6	Interventions 653 671	placebo-controlled
T7	Interventions 726 744	placebo-controlled
T8	Interventions 950 984	on stable lipid-regulating therapy
T9	Interventions 1137 1186	receive subcutaneous evolocumab 420 mg or placebo
T10	Interventions 1319 1370	by a computerised interactive voice-response system
T11	Interventions 1975 1986	the placebo
T12	Interventions 2003 2017	the evolocumab
T13	Interventions 2035 2059	with placebo, evolocumab
T14	Interventions 2238 2253	patients in the
T15	Interventions 2284 2304	33 in the evolocumab
T16	Interventions 2375 2393	no anti-evolocumab
T17	Interventions 2584 2605	apheresis, evolocumab
T18	Interventions 2701 2714	compared with